FX.co ★ Orexo Announces Positive Data From Clinical Study Of OX640 Evaluating Allergic Reactions

Orexo AB (ORXOY.OB), a Swedish pharmaceutical firm, announced on Friday promising results from a clinical study involving OX640, a rescue nasal medication that uses a powder-based epinephrine formulation to counter allergic reactions. The study revealed that OX640 treatments reached clinically significant plasma levels of epinephrine when compared to the standard intramuscular reference product. Additionally, the pharmacokinetic and pharmacodynamic assessments in participants, both with and without allergic rhinitis, indicated a swift onset of action in patients who exhibited airway symptoms. The formulations of OX640 generally resulted in more notable increases in blood pressure and heart rate than the intramuscular injection, which are critical effects for the management of anaphylaxis. Importantly, no severe or serious adverse events were reported.